565 related articles for article (PubMed ID: 19092849)
61. 4-arylcoumarin analogues of combretastatins stimulate apoptosis of leukemic cells from chronic lymphocytic leukemia patients.
Billard C; Menasria F; Quiney C; Faussat AM; Finet JP; Combes S; Kolb JP
Exp Hematol; 2008 Dec; 36(12):1625-33. PubMed ID: 18922614
[TBL] [Abstract][Full Text] [Related]
62. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
[TBL] [Abstract][Full Text] [Related]
63. Expression levels of Lyn, Syk, PLCγ2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival.
Wang YH; Fan L; Wang L; Zhang R; Zou ZJ; Fang C; Zhang LN; Li JY; Xu W
Leuk Lymphoma; 2013 Jun; 54(6):1165-70. PubMed ID: 23039362
[TBL] [Abstract][Full Text] [Related]
64. Syk, but not Lyn, recruitment to B cell antigen receptor and activation following stimulation of CD45- B cells.
Pao LI; Cambier JC
J Immunol; 1997 Mar; 158(6):2663-9. PubMed ID: 9058799
[TBL] [Abstract][Full Text] [Related]
65. Swiprosin-1/EFhd2 controls B cell receptor signaling through the assembly of the B cell receptor, Syk, and phospholipase C gamma2 in membrane rafts.
Kroczek C; Lang C; Brachs S; Grohmann M; Dütting S; Schweizer A; Nitschke L; Feller SM; Jäck HM; Mielenz D
J Immunol; 2010 Apr; 184(7):3665-76. PubMed ID: 20194721
[TBL] [Abstract][Full Text] [Related]
66. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.
Ghosh AK; Secreto C; Boysen J; Sassoon T; Shanafelt TD; Mukhopadhyay D; Kay NE
Blood; 2011 Feb; 117(6):1928-37. PubMed ID: 21135257
[TBL] [Abstract][Full Text] [Related]
67. Normal Syk protein level but abnormal tyrosine phosphorylation in B-CLL cells.
Semichon M; Merle-Béral H; Lang V; Bismuth G
Leukemia; 1997 Nov; 11(11):1921-8. PubMed ID: 9369427
[TBL] [Abstract][Full Text] [Related]
68. Suboptimal B-cell antigen receptor signaling activity in vivo elicits germinal center counterselection mechanisms.
Königsberger S; Weis V; Prodöhl J; Stehling M; Hobeika E; Reth M; Kiefer F
Eur J Immunol; 2015 Feb; 45(2):603-11. PubMed ID: 25382621
[TBL] [Abstract][Full Text] [Related]
69. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia.
Balakrishnan K; Burger JA; Fu M; Doifode T; Wierda WG; Gandhi V
Neoplasia; 2014 Dec; 16(12):1036-46. PubMed ID: 25499217
[TBL] [Abstract][Full Text] [Related]
70. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP
J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460
[TBL] [Abstract][Full Text] [Related]
71. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
72. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
Leonhardt F; Zirlik K; Buchner M; Prinz G; Hechinger AK; Gerlach UV; Fisch P; Schmitt-Gräff A; Reichardt W; Zeiser R
Leukemia; 2012 Jul; 26(7):1617-29. PubMed ID: 22301676
[TBL] [Abstract][Full Text] [Related]
73. Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.
Dielschneider RF; Xiao W; Yoon JY; Noh E; Banerji V; Li H; Marshall AJ; Johnston JB; Gibson SB
Cell Death Dis; 2014 Oct; 5(10):e1439. PubMed ID: 25275600
[TBL] [Abstract][Full Text] [Related]
74. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation.
Fujimoto M; Poe JC; Jansen PJ; Sato S; Tedder TF
J Immunol; 1999 Jun; 162(12):7088-94. PubMed ID: 10358152
[TBL] [Abstract][Full Text] [Related]
75. The Syk kinase as a therapeutic target in leukemia and lymphoma.
Efremov DG; Laurenti L
Expert Opin Investig Drugs; 2011 May; 20(5):623-36. PubMed ID: 21438742
[TBL] [Abstract][Full Text] [Related]
76. Can treating the SYK cell cure leukemia?
Downing JR
Cancer Cell; 2009 Oct; 16(4):270-1. PubMed ID: 19800569
[TBL] [Abstract][Full Text] [Related]
77. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.
Contri A; Brunati AM; Trentin L; Cabrelle A; Miorin M; Cesaro L; Pinna LA; Zambello R; Semenzato G; Donella-Deana A
J Clin Invest; 2005 Feb; 115(2):369-78. PubMed ID: 15650771
[TBL] [Abstract][Full Text] [Related]
78. Role of protein-tyrosine kinase syk in oxidative stress signaling in B cells.
Takano T; Sada K; Yamamura H
Antioxid Redox Signal; 2002 Jun; 4(3):533-41. PubMed ID: 12215221
[TBL] [Abstract][Full Text] [Related]
79. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
Chen R; Tsai J; Thompson PA; Chen Y; Xiong P; Liu C; Burrows F; Sivina M; Burger JA; Keating MJ; Wierda WG; Plunkett W
Blood Cancer J; 2021 Mar; 11(3):57. PubMed ID: 33714981
[TBL] [Abstract][Full Text] [Related]
80. Survival of leukemic B cells promoted by engagement of the antigen receptor.
Bernal A; Pastore RD; Asgary Z; Keller SA; Cesarman E; Liou HC; Schattner EJ
Blood; 2001 Nov; 98(10):3050-7. PubMed ID: 11698290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
